LMR Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $110K | Buy |
143
+26
| +22% | +$19.9K | ﹤0.01% | 1254 |
|
|
2025
Q4 | $90.3K | Sell |
117
-15,457
| -99% | -$10.5M | ﹤0.01% | 1353 |
|
|
2025
Q3 | $8.76M | Sell |
15,574
-28,070
| -64% | -$15.9M | 0.04% | 363 |
|
|
2025
Q2 | $22.9M | Buy |
+43,644
| New | +$24.4M | 0.16% | 132 |
|
|
2024
Q4 | – | Sell |
-229
| Closed | -$241K | – | 1534 |
|
|
2024
Q3 | $241K | Buy |
+229
| New | +$255K | ﹤0.01% | 954 |
|
|
2024
Q2 | – | Sell |
-197
| Closed | -$190K | – | 1273 |
|
|
2024
Q1 | $190K | Buy |
197
+28
| +17% | +$26.6K | ﹤0.01% | 875 |
|
|
2023
Q4 | $148K | Sell |
169
-327
| -66% | -$269K | ﹤0.01% | 745 |
|
|
2023
Q3 | $408K | Sell |
496
-317
| -39% | -$249K | ﹤0.01% | 578 |
|
|
2023
Q2 | $584K | Buy |
+813
| New | +$627K | 0.01% | 477 |
|
|
2023
Q1 | – | Sell |
-9,766
| Closed | -$7.05M | – | 1151 |
|
|
2022
Q4 | $7.05M | Buy |
+9,766
| New | +$7.21M | 0.12% | 207 |
|
|
2022
Q3 | – | Sell |
-2,573
| Closed | -$1.52M | – | 1290 |
|
|
2022
Q2 | $1.52M | Buy |
2,573
+2,111
| +457% | +$1.37M | 0.03% | 607 |
|
|
2022
Q1 | $323K | Buy |
+462
| New | +$292K | ﹤0.01% | 1064 |
|
|
2021
Q4 | – | Sell |
-2,637
| Closed | -$1.6M | – | 1254 |
|
|
2021
Q3 | $1.6M | Buy |
2,637
+1,757
| +200% | +$1.09M | 0.02% | 508 |
|
|
2021
Q2 | $492K | Buy |
+880
| New | +$446K | 0.01% | 669 |
|
|
2021
Q1 | – | Sell |
-1,625
| Closed | -$785K | – | 1045 |
|
|
2020
Q4 | $785K | Buy |
+1,625
| New | +$877K | 0.01% | 308 |
|
|
2020
Q3 | – | Sell |
-17,276
| Closed | -$10.8M | – | 601 |
|
|
2020
Q2 | $10.8M | Buy |
17,276
+15,759
| +1,039% | +$8.95M | 0.27% | 62 |
|
|
2020
Q1 | $718K | Sell |
1,517
-789
| -34% | -$325K | 0.03% | 150 |
|
|
2019
Q4 | $866 | Sell |
2,306
-1,449
| -39% | -$488K | ﹤0.01% | 232 |
|
|
2019
Q3 | $1.04M | Buy |
+3,755
| New | +$1.11M | 0.05% | 164 |
|
|
2018
Q2 | – | Sell |
-1,405
| Closed | -$528K | – | 567 |
|
|
2018
Q1 | $528K | Hold |
1,405
| – | – | 0.05% | 247 |
|
|
2017
Q4 | $528K | Buy |
1,405
+618
| +79% | +$250K | 0.05% | 247 |
|
|
2017
Q3 | $352K | Sell |
787
-3,003
| -79% | -$1.43M | 0.04% | 224 |
|
|
2017
Q2 | $1.86M | Sell |
3,790
-1,219
| -24% | -$533K | 0.12% | 182 |
|
|
2017
Q1 | $1.94M | Buy |
+5,009
| New | +$1.86M | 0.19% | 85 |
|
|
2016
Q3 | – | Sell |
-1,549
| Closed | -$541K | – | 455 |
|
|
2016
Q2 | $541K | Buy |
1,549
+698
| +82% | +$269K | 0.08% | 274 |
|
|
2016
Q1 | $307 | Sell |
851
-771
| -48% | -$318K | 0.03% | 322 |
|
|
2015
Q4 | $881K | Buy |
1,622
+624
| +63% | +$338K | 0.29% | 73 |
|
|
2015
Q3 | $464K | Sell |
998
-7,205
| -88% | -$3.87M | 0.05% | 226 |
|
|
2015
Q2 | $4.18M | Buy |
8,203
+4,457
| +119% | +$2.18M | 0.51% | 30 |
|
|
2015
Q1 | $1.69M | Buy |
3,746
+808
| +28% | +$342K | 0.23% | 118 |
|
|
2014
Q4 | $1.21M | Sell |
2,938
-43,116
| -94% | -$17M | 0.16% | 181 |
|
|
2014
Q3 | $16.6M | Buy |
+46,054
| New | +$15.4M | 1.32% | 25 |
|
Other funds holding REGN
VCM
N
LMR Partners's REGN Position: Q1 2026 in Review
LMR Partners increased its Regeneron Pharmaceuticals (REGN) stake by 22% in Q1 2026, buying an estimated $19.9K and bringing the position to 143 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #1254.
LMR Partners first reported a position in REGN in Q3 2014 and has held it in 32 quarters since. The position peaked at $22.9M in Q2 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- LMR Partners held 143 shares of Regeneron Pharmaceuticals worth $110K as of Q1 2026.
- LMR Partners bought 26 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $19.9K.
- Regeneron Pharmaceuticals made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1254 holding.
- LMR Partners first reported a position in Regeneron Pharmaceuticals in Q3 2014 and has held it in 32 quarters since.
- LMR Partners's Regeneron Pharmaceuticals position peaked at $22.9M in Q2 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.